Radionetics Oncology
Umesh Gangadharmath is a seasoned professional with extensive experience in the field of radiochemistry and radiopharmaceutical development. He has held key positions in various companies and research institutions, contributing significantly to the advancement of PET imaging agents and novel cancer targets. His expertise in scientific research, chemistry, and regulatory affairs has been instrumental in successful collaborations and developments within the industry. With a strong educational background in inorganic chemistry, Umesh brings valuable knowledge and skills to his current role as SVP of Technical Operations and CMC at Radionetics Oncology.
Radionetics Oncology
Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company’s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.